ClinicalTrials.Veeva

Menu

An Observational Study of Lung Cancer Related Symptoms and Disease Control Rate in Patients With Non-Small Cell Lung Cancer Receiving First-Line Platinum-Based Chemotherapy With or Without Avastin (Bevacizumab)

Roche logo

Roche

Status

Completed

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Study type

Observational

Funder types

Industry

Identifiers

NCT01358942
ML25493

Details and patient eligibility

About

This prospective observational study will evaluate the evolution of lung cancer related symptoms and their correlation with the disease control rate (complete response, partial response and stable disease) in patients with non-small cell lung cancer initiating first-line treatment with standard platinum-based chemotherapy with or without Avastin (bevacizumab). Data will be collected from each patient at baseline and after 4-6 cycles of chemotherapy.

Enrollment

156 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patients, >/= 18 years of age
  • Histologically or cytologically confirmed non-small cell lung cancer
  • Initiating first-line treatment with standard platinum-based chemotherapy, with or without bevacizumab

Exclusion criteria

  • Contraindications to the use of platinum-based chemotherapy

Trial design

156 participants in 1 patient group

Cohort

Trial contacts and locations

37

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems